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Buonfiglioli et al. elucidate the role of let-7
miRNAs acting as Toll-like receptor (TLR)
ligands in the brain. Select let-7 miRNAs
function as signaling molecules to
modulate diverse microglial functions
and glioma growth through TLR7. These
data establish let-7 miRNAs as TLR7
signaling activators of microglia in health
and glioma.
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Microglia express Toll-like receptors (TLRs) that
sense pathogen- and host-derived factors, including
single-stranded RNA. In the brain, let-7 microRNA
(miRNA) family members are abundantly expressed,
and some have recently been shown to serve as
TLR7 ligands. We investigated whether let-7 miRNA
family members differentially control microglia
biology in health and disease.We found that a subset
of let-7 miRNA family members function as signaling
molecules to induce microglial release of inflamma-
tory cytokines, modulate antigen presentation, and
attenuate cell migration in a TLR7-dependent
manner. The capability of the let-7miRNAs to control
microglial function is sequence specific, mapping to
a let-7 UUGU motif. In human and murine glioblas-
toma/glioma, let-7 miRNAs are differentially ex-
pressed and reduce murine GL261 glioma growth in
the same sequence-specific fashion through micro-
glial TLR7. Taken together, these data establish
let-7 miRNAs as key TLR7 signaling activators that
serve to regulate the diverse functions of microglia
in health and glioma.3460 Cell Reports 29, 3460–3471, December 10, 2019 ª 2019 The A
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MicroRNAs (miRNAs) are short, non-coding single-stranded RNA
(ssRNA) molecules, shown to posttranscriptionally regulate gene
expression (Bartel, 2004). The lethal-7 (let-7) miRNA family, the
first miRNA family identified in humans (Pasquinelli et al., 2000),
includes nine mature members (let-7a–let-7i and miR-98). let-7
miRNAs, which are abundantly expressed in the brain and exhibit
high cross-species sequence conservation (Pena et al., 2009;
Reinhart et al., 2000), have been shown to regulate cell differenti-
ation and brain tumor growth (Gilles and Slack, 2018; Lee et al.,
2016). miRNAs are also present in the extracellular space, derived
either from dying cells or actively released within vesicles (e.g.,
exosomes), where they function as signaling molecules (Feng
et al., 2017; Lehmann et al., 2012a). Some miRNAs can serve
as ligands for Toll-like receptors (TLRs) (Fabbri et al., 2012;
Feng et al., 2017; Lehmann et al., 2012a). TLRs belong to a family
of pattern recognition receptors, which recognize pathogen-
associated molecules, such as bacterial and viral components,
and damage-associated molecules derived from necrotic cells
and tumor tissue (Tang et al., 2012). Upon activation, TLRs signal
through a complex array of effector proteins resulting in inflamma-
tion (Kawai and Akira, 2006). Importantly, there is sequence spec-
ificity to miRNA engagement of TLRs, in that the GUUGUGU
motif, found in let-7b, is required for TLR7 recognition of
ssRNA40, a nucleotide derived from HIV (Heil et al., 2004).uthor(s).
commons.org/licenses/by/4.0/).
Microglia respond to brain pathological states bymigrating to-
ward the lesion site, releasing inflammatory molecules, engulfing
cell debris (Napoli and Neumann, 2009), and presenting disease-
associated antigen, thereby contributing to CNS disease patho-
biology (Wlodarczyk et al., 2014). Some of these responses are
mediated by TLRs, such as TLR7, which detects ssRNA (Diebold
et al., 2004; Heil et al., 2004) and controls microglial chemotaxis
(Ifuku et al., 2016). Additional TLRs regulate microglial motility
(TLR2; Ifuku et al., 2016) and phagocytosis of Ab amyloid in Alz-
heimer’s disease (TLR4; Rajbhandari et al., 2014). In the setting
of glioblastoma (GBM), themost aggressive brain tumor in adults
with survival of less than 15 months from diagnosis (Louis et al.,
2016; Stupp et al., 2005), TLR2 and TLR4 control the interaction
between glioma cells and microglia, thereby promoting tumor
expansion (Dzaye et al., 2016; Hu et al., 2015; Vinnakota et al.,
2013). Glioma-associated microglia and invading peripheral
macrophages constitute up to 30%of the tumor tissue, adopting
a tumor-supportive phenotype (Hambardzumyan et al., 2016).
Here, we systematically analyzed the different members of the
let-7miRNA family to determine which of these molecules func-
tion as microglial TLR signaling molecules. We found that a
defined subset of the let-7miRNA family, characterized by a spe-
cific nucleotide sequence, activates TLR7 and modulates micro-
glial release of inflammatory cytokines, migration, and antigen
presentation. This selectivity operates in the setting of GBM, in
which select let-7 miRNAs inhibit tumor growth via microglial
TLR7 signaling. Our data establish that let-7miRNA dictates mi-
croglial function through TLR7 signaling, which is important for
physiological and pathological processes in the CNS.
RESULTS AND DISCUSSION
Select Members of the let-7 miRNA Family Activate
Microglia via TLR7 Signaling
Microglia are the resident immune cells of the CNS, where they
function as sensors of changes in their environment caused by
invading pathogens and host-derived factors. Following activa-
tion, microglia migrate to the lesion site and secrete cytokines
and chemokines (Kettenmann et al., 2011). These responses
are regulated in part by TLRs. Consistent with a central role for
TLRs in brain homeostasis, miRNAs serve as TLR signaling acti-
vators (Fabbri et al., 2012; Feng et al., 2017; He et al., 2013; Leh-
mann et al., 2012a). miRNA dysregulation is linked to inflamma-
tory and immune responses, which modulate cancer initiation
and progression (Gilles and Slack, 2018). On the basis of
sequence similarity to known TLR7 ligands, such as the oligori-
bonucleotide ssRNA40 derived fromHIV, their abundant expres-
sion in the CNS, and their key role in immune responses in pa-
thology including cancer, we focused on the let-7 miRNA
family members as potential signaling activators of microglia in
health and in the setting of GBM. To this end, first we sought
to systematically investigate the potential of different let-7
miRNA family members (Table S1) to activate TLR7 in microglia.
Cultured microglia from neonatal wild-type (WT) mice were incu-
bated for 9, 24, and 30 h with synthetic oligoribonucleotides
derived from the let-7 miRNA family at different concentrations
(1, 5, and 10 mg/mL), and analyzed for TNF-a release using
ELISA. Lipopolysaccharide (LPS) and loxoribine (LOX) servedas positive controls for TLR4 and TLR7 activation, respectively.
let-7a, let-7b, let-7c, let-7e, let-7f, and let-7g induced TNF-a
release from microglia time- and dose-dependently (Figure 1A).
There was increased TNF-a release after 24 h relative to 9 h,
while after 30 h, at 5 mg/mL, there was no further increase.
TNF-a release in response to 5 mg/mL let-7 miRNA was higher
compared with 1 mg/mL, but not much different at 10 mg/mL after
24 h. let-7 miRNA-induced responses were sequence specific,
as control oligoribonucleotides with a mutant sequence did not
induce TNF-a release. In contrast to the responses triggered
by the let-7 miRNAs above, TNF-a induced by let-7d, let-7i,
and miR-98 was only slightly increased relative to control (Fig-
ure 1A). Using biotinylated let-7b, we confirmed that extracellu-
larly delivered let-7miRNA entersmicroglia (Figure 1B). To deter-
mine whether TLR7 is required for microglial activation by let-7
miRNAs,microglia fromneonatal Tlr7/micewere investigated.
In contrast to WT microglia, TLR7-deficient microglia failed to
release amounts of TNF-a in response to stimulation with any
of the members of the let-7 miRNA family at 5 mg/mL within
24 h (Figure 1C). As expected, stimulation with LOX was abol-
ished in Tlr7/ mice, while LPS- and Pam2CSK4 (ligand for
TLR2)-induced responses were unaffected. Stimulation of
Tlr7/ microglia with different doses (1, 5, or 10 mg/mL) of any
of the let-7 miRNAs within 24 h or with 5 mg/mL let-7 miRNA
over different time periods (9, 24, or 30 h) did not result in signif-
icant TNF-a production compared with control (Figure S1). To
exclude the possibility that the effects were due to contamination
with TLR4 and/or TLR2 ligands, such as LPS or lipoproteins, we
testedmicroglia from Tlr2/ and Tlr4/mice (Figure 1C). TLR2-
and TLR4-deficient microglia released TNF-a in response to the
same let-7 family members that activated WT microglia. TNF-a
release induced by LPS in TLR4-deficient microglia, and by the
TLR2 agonist Pam2CSK4 in TLR2-deficient microglia, was
abolished.
To test whether let-7-mediated activation of microglia depends
on their developmental stage or the isolation procedure, we
compared TNF-a release triggered by let-7 family members in
postnatal microglia cultures to microglia from adult tissue and
freshly isolated adult microglia. Adult microglia were isolated
from8-week-oldmice andwere grown in vitro for 3weeks. Freshly
isolated microglia were obtained from 12-week-old mice via fluo-
rescence-activatedcell sorting (FACS)andwereseededovernight
before stimulation. Cells were stimulated with the different let-7
familymembers and analyzed using ELISA (Figure 2). Adult micro-
glia and freshly isolated adult microglia released TNF-a in
response to let-7b, let-7c, let-7e, let-7f, and let-7g. Compared
with neonatal microglia, these responses were smaller in magni-
tude. As observed in neonatal microglia, adult microglia and
freshly isolated adult microglia exhibited little TNF-a release in
response to let-7a, let-7d, let-7i, ormiR-98 stimulation (Figure 2).
Thesemicroglial responsesweresequencespecific, ascontrol oli-
goribonucleotides with a mutant sequence did not induce TNF-a
release. To confirm let-7 miRNAs as signaling activators of im-
mune cells, not only in the CNS but also in the periphery, we
analyzed bone marrow-derived macrophages using the same
experimental protocol. Monocytes were isolated from bone mar-
rows of 8-week-old mice and differentiated into macrophages
for 6 days. We observed a sequence-specific release of TNF-aCell Reports 29, 3460–3471, December 10, 2019 3461
Figure 1. Extracellularly Delivered Different let-7 miRNA Family Members Trigger TNF-a Release from Microglia Time- and Dose-Depen-
dently via TLR7, but Not TLR2 or TLR4
(A) Primary neonatal microglia from wild-type (WT) mice were stimulated with 5 mg/mL of let-7a-let-7i or miR-98 oligoribonucleotides for 9, 24, or 30 h (top) or
with 1, 5, or 10 mg/mL of let-7a-let-7i or miR-98 oligoribonucleotides for 24 h (bottom). TNF-a release was determined using ELISA. Lipopolysaccharide (LPS;
100 ng/mL) and loxoribine (LOX; 1 mM) were used as known TLR4 and TLR7 activators, respectively, while mutant oligoribonucleotide (mut. oligo; 5 mg/mL) and
LyoVec served as negative controls. n = 5.
(B) Representative images of cultured neonatal microglia fromWT mice incubated with 5 mg/mL biotinylated let-7b for 6 h. Cells were stained with Iba1 antibody
and DAPI. Unstimulated microglia served as control. Scale bar, 30 mm.
(C) Primary neonatal microglia from WT, Tlr7/, Tlr2/, and Tlr4/ mice were stimulated with 5 mg/mL let-7a- let-7i and miR-98 for 24 h. TNF-a release was
determined using ELISA. LPS (100 ng/mL), LOX (1 mM), and Pam2CSK4 (100 ng/mL) were used as positive controls for TLR4, TLR7, and TLR2 activation,
respectively, while incubation with mut. oligo (5 mg/mL) and LyoVec served as negative controls. n = 5.
Data are represented as mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 versus control (Kruskal-Wallis followed by Dunn’s post hoc test).
See also Figure S1 and Table S1.from bone marrow-derived macrophages stimulated with let-7b,
let-7e, let-7f, and let-7g (Figure 2). In contrast to microglia,
TNF-a release at 24 and 30 hwas not different fromTNF-a release
at 9 h (Figure S2). let-7d, let-7i, and miR-98 stimulation did not
result in TNF-a production in macrophages (Figure 2). Taken
together, extracellularly delivered let-7 miRNAs differentially
induce microglial activation through TLR7. The ability of microglia
to respond to let-7 miRNAs does not depend on their develop-
mental stage, implying a functional role for extracellular let-7
miRNAs in CNS diseases occurring at all ages. The precise local
concentrations of extracellularly functional let-7b (or other mem-
bers of the let-7 miRNA family) in the brain parenchyma at the
site of injury/pathology in vivo are not known. For this reason, the
concentrations of let-7 miRNAs used in the present study were
based on our previouswork on ssRNA-mediated neurodegenera-
tion, in which we found that injured neurons, and potentially other3462 Cell Reports 29, 3460–3471, December 10, 2019CNS cells, release let-7b into the extracellular space (Lehmann
et al., 2012a, 2012b). Future work will be required to determine
pathophysiological concentrations of let-7miRNAs in the brain.
Select let-7 miRNAs Induce a Specific Pattern of
Inflammatory Molecules Released from Microglia
through TLR7
Although TNF-a is a well-studied cytokine released in response
to TLR activation, additional cytokines and chemokines are
also released from microglia. To determine the specific inflam-
matory response pattern induced by let-7 miRNAs via TLR7,
we used a multiplex immunoassay and analyzed the superna-
tants from neonatal WT and Tlr7/ microglia incubated with
5 mg/mL of the respective let-7 miRNA family member after
24 h. Mutant oligoribonucleotide and the TLR7 ligand LOX
served as controls. IL-6, IL-10, IL-1b, GRO-a, MIP-2, and
Figure 2. Neonatal and Adult Microglia, as Well as Bone Marrow-
Derived Macrophages, Respond to Extracellularly Delivered let-7
miRNAs
Primary cultured neonatal, adult cultured microglia, freshly isolated microglia,
and primary bone marrow-derived macrophages from adult WT mice were
stimulated with 5 mg/mL let-7a-let-7i or miR-98 oligoribonucleotides, as indi-
cated, for 24 h. TNF-a levels were determined using ELISA. LPS (100 ng/mL)
and LOX (1 mM) were used as TLR4 and TLR7 ligands, respectively. Mut. oligo
(5 mg/mL) and LyoVec served as negative controls. n = 4–6. Data are repre-
sented as mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 versus control
(Kruskal-Wallis followed by Dunn’s post hoc test).
See also Figure S2.
Figure 3. Characterization of the Microglial Inflammatory Response
and Antigen-Presenting Marker Expression Induced by let-7 miR-
NAs through TLR7
(A) Multiplex immunoassay was performed to characterize the inflammatory
response in WT (top) and Tlr7/ (bottom) microglia in response to let-7b, let-
7d, and let-7e using the supernatants collected for TNF-a analysis in Figure 1.
Data are shown in a heatmap representing cytokine release expressed in
logarithmic of mean fluorescence intensity (MFI). LPS, LOX, andmut. oligo and
LyoVec were used as positive and negative controls, respectively. n = 5. For p
values yielded by Kruskal-Wallis test followed by Dunn’s multiple comparison
post hoc test, refer to Table S2.
(B) Primary neonatal microglia from WT and Tlr7/ mice were incubated
with 5 mg/mL let-7b, let-7d, and let-7e for 24 h. MHC I, MHC II, and
CD54 expression were analyzed using FACS. Marker expression is
shown as mean fluorescent intensity (MFI) normalized to unstimulated
control. LPS (100 ng/mL), LOX (1 mM), and IFN-g (100 ng/mL) served as
positive controls. Mut. oligo (5 mg/mL) and LyoVec served as negative
controls. n = 4–10.
Data are represented as mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001
versus control (one-way ANOVA followed by Bonferroni post hoc test).
See also Figures S3 and S4 and Table S3.RANTES were released from WT microglia after let-7a, let-7b,
let-7c, let-7e, let-7f, and let-7g stimulation in a sequence-depen-
dent fashion, while incubation with let-7d, let-7i, or miR-98 did
not result in much cytokine release (Figure 3A; Table S2). GM-
CSF, IP-10, MCP-1, and MCP-3 were not increased after stimu-
lation with any of the let-7 miRNAs tested (Figure S3; Table S3).
IL-6, IL-10, IL-1b, GRO-a, MIP-2, and RANTES induction
required TLR7, as TLR7-deficient cells failed to respond to
let-7 miRNA (Figure 3A). MIP-1a and MIP-1b were released
from microglia in response to all tested let-7 miRNAs, but this
response was not dependent on TLR7 (Figure S3). In summary,
selected extracellularly delivered let-7 miRNA family members
induce a sequence-specific and TLR7-dependent inflammatory
response with a distinct profile of cytokine release. AlthoughCell Reports 29, 3460–3471, December 10, 2019 3463
Figure 4. Small Oligoribonucleotides Including let-7miRNAs Induce
Chemotaxis in Microglia via TLR7
Microglial migration in response to let-7b, let-7d, and let-7e oligoribonucleo-
tides was analyzed by agarose spot assay.
(A) Images of let-7b-treated and control microglial cultures from WT and
Tlr7/ mice. Scale bar, 100 mm.
(B) let-7b, let-7d, or let-7e (5 mg/mL) was added either to the spot alone
(gradient/black) or both to the spot and the culture medium (no gradient/dark
gray) with (light gray) or without RNase A pre-incubation. Microglial migration
in response to 5 mg/mL let-7b, let-7d, or let-7e was also analyzed in Tlr7/
(white) microglia. PBS was used as negative control. Microglial migration was
analyzed after 3 h of incubation. n = 8.
Data are represented as mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001
versus control (one-way ANOVA followed by Bonferroni post hoc test).some of the inflammatory molecules, including TNF-a, IL-6, and
IL-1b, have previously been reported as outputs of increased
TLR7 signaling (Petes et al., 2017) and in the setting of glioma
(Dzaye et al., 2016; Bowman et al., 2016; Zhu et al., 2012), the
pattern of cytokines and chemokines determined in our study re-
flects the specific let-7 miRNA family member used to stimulate
microglia. Because let-7 miRNAs differ only slightly within their
GU-rich sequence motifs (see below), these data explain how in-
dividual miRNAs serving as signaling molecules may modify
CNS inflammation in a sequence-dependent manner. In addi-
tion, our findings raise the possibility that specific combinations
of inflammatory molecules may uniquely affect brain disease
pathogenesis. For example, select let-7miRNA family members
induce IL-6 release from microglia, which has been previously
shown to promote the invasiveness of glioma cells (Zhang
et al., 2012).
let-7b and let-7e Modulate the Expression of Antigen-
Presenting Markers via TLR7
Microglia act as antigen-presenting cells in the CNS, regulating
innate and adaptive immune responses. Major histocompatibility
complex (MHC) class I is expressed by all nucleated cells and is
responsible for theactivationofCD8+Tcellsandnatural killer cells,
while MHC II is expressed by immune cells and activates CD4+
T cells. CD54 (ICAM-1) is also important for antigen presentation
(Werner et al., 1998; Zuckerman et al., 1998). Microglia from
WT and Tlr7/ mice were analyzed using FACS for MHC I,3464 Cell Reports 29, 3460–3471, December 10, 2019MHC II, and CD54 expression following stimulation with 5 mg/mL
let-7band let-7e,whichwereobserved to induceapotentcytokine
response in microglia, and let-7d, which comparatively induced a
weak cytokine response, for 24 h. LPS, loxoribine and IFN-gwere
used as positive controls for TLR4 and TLR7 activation, as well as
general microglial activation, respectively (Figure 3B; for FACS
gating strategy and histogram plots, see Figure S4). Treatment
with let-7b and let-7e, but not let-7d, increased MHC I, but not
MHC II, expression. CD54 expression was increased in response
to let-7b and let-7e and to a lesser extent to let-7d inmicroglia. let-
7-miRNA-induced upregulation of MHC I and CD54 expression
required TLR7, as Tlr7/ microglia did not respond to the treat-
ments (Figure 3B). In summary, select let-7 miRNAs affected the
expression of specific molecules crucial for antigen presentation
in the CNS. MHC I and CD54 expression was dependent on
TLR7. Both molecules are important for the communication be-
tween innate and adaptive immune cells. Specifically, MHC I is
recognized by cytotoxic T cells, triggering an immediate immune
response against a non-self-antigen, and natural killer cells, which
directly kill antigen-presenting cells, such as virus-infected or tu-
mor cells. Whether MHC I and CD54 expression in microglia in
response to let-7miRNAs directly triggers T cell and natural killer
cell activation remains unexplored at this stage and requires
further investigation.
Select let-7 miRNAs Induce Chemotaxis, but Not
Motility, in Microglia through TLR7
In response to brain injury or pathology, microglia migrate to the
afflicted sites, where they phagocytose pathogens, apoptotic
cells, and cellular debris. We have previously shown that chemo-
taxis is controlled by TLR7 in microglia (Ifuku et al., 2016). As
let-7 miRNAs were found to serve as signaling activators of
TLR7 in microglia, thereby inducing an inflammatory response,
we investigated the let-7 miRNAs’ impact on microglial migra-
tion. To this end, microglia stimulated with let-7b, let-7e, and
let-7d were analyzed using an agarose spot assay with a
gradient to evaluate directed migration or without a gradient to
test motility (Figures 4A and 4B). The let-7 miRNAs as well as
mutant oligoribonucleotides were added either to the spot
alone or into both the spot and the medium. Cells that entered
the spot within 3 h were quantified. PBS was used as negative
control. let-7b, let-7d, and let-7e, but also the mutant oligoribo-
nucleotide, increased microglial chemotaxis, but not motility,
compared with control (Figure 4B), suggesting that small RNA
molecules induce chemotaxis of microglia, independent of
their sequence. Pre-treatment of the oligoribonucleotides with
RNase A abolished migration, confirming the specificity of mi-
croglial migration induced by ssRNAs (Figure 4B). To determine
whether TLR7 is involved in microglial migration induced by
small oligoribonucleotides, we performed agarose spot assay
with microglia from Tlr7/ mice, using the same protocol previ-
ously used for WT microglia. TLR7-deficient microglia did not
show increased migration when incubated with let-7b, let-7d,
let-7e, or mutant oligoribonucleotides compared with control,
implying that the migratory effect on microglia is dependent on
TLR7 (Figures 4A and 4B). Taken together, incubation of micro-
glia with let-7b, let-7d, and also let-7e led to increasedmigration.
Our finding that a mutant control oligoribonucleotide lacking the
Figure 5. UUGU Is the Minimal Motif in let-7 miRNAs Required for
Activation of Microglial TLR7
(A) Sequences of let-7 miRNA family members with indicated GU-rich TLR7
recognition motifs.
(B) Representation of let-7d’s and let-7e’s core motifs and corresponding
mutations (red).
(C) Supernatants fromWTmicroglia stimulated with 5 mg/mL of unmodified let-
7e and let-7d, as well as with 5 mg/mL of the mutated oligoribonucleotides let-
7d-mut-N, let-7e-mut-N, and let-7-mut-CS, for 24 h were analyzed by TNF-a
ELISA. n = 3.
Data are represented as mean ± SEM. ***p < 0.001 mutated oligoribonucleo-
tide versus respective naive oligoribonucleotide (one-way ANOVA followed by
Bonferroni post hoc test).GU-rich core motif also attracted microglia was unexpected and
implies that, in contrast to the inflammatory response, microglial
migration is modulated by small RNA in general but is not depen-
dent on their sequence. Although we observed modulation of in-
flammatory response, antigen presentation, and migration by
extracellularly delivered let-7 miRNAs, we did not observe any
effect on microglial phagocytosis (unpublished data).
The selective modulation of microglial functions suggests that
let-7, and perhaps other miRNA species, elicit a specific reprog-
ramming of microglia that promotes some, but not all, physiolog-
ical processes important for brain homeostasis. Still, the findings
reported herein so far raise several important points regarding
microglia function in the brain. First, microglial activation
following let-7 exposure is a highly specific cellular response. It
is not due to non-specific binding and/or the presence of
contaminating factors. To this end, we used both a highly puri-
fied control mutant oligoribonucleotide, in which the GU content
of the let-7 core motif was modified, and oligoribonucleotides, in
which single nucleotides of the let-7 miRNA’s sequence motifs
were exchanged. Both control groups of oligoribonucleotides
were handled and prepared identically to the respective let-7
miRNA tested, making it unlikely that the microglial response
to the let-7 miRNA family was unspecific. TLR2- and TLR4-defi-
cient but not TLR7-deficient microglia responded in a similar way
to let-7 miRNAs as WT microglia, excluding the possibility thatmicroglial activation after let-7 miRNA incubation was due to
the presence of endotoxin or lipoproteins. These responses
occurred independent of microglia developmental stage (Schef-
fel et al., 2012), as neonatal and adult microglia behaved simi-
larly. Finally, RNase treatment of let-7miRNAs abolished micro-
glial migration, confirming the RNA nature of the agents tested.
The Sequence Motif UUGU Is Required for let-7miRNA-
Induced Activation of TLR7 in Microglia
let-7 miRNA family members exhibit different capacities to acti-
vate microglia, reflecting sequence specificity. The let-7 miRNA
family is highly conserved between and within species, differing
only in 1–4 nt among its members (Roush and Slack, 2008). As
such, let-7b possesses a sequence that contains the established
TLR7 recognition motif GUUGUGUwithin its 30 terminus (Diebold
et al., 2004; Heil et al., 2004; Lehmann et al., 2012a). Other let-7
miRNAs such as let-7a, let-7c, let-7d, let-7e, let-7f, let-7g, let-7i,
and miR-98 contain similar GU-rich motifs with minimal ex-
changes of nucleotides (Roush and Slack, 2008). To determine
the minimal motif within let-7 being necessary for microglial acti-
vation through TLR7, we used mutagenesis strategies, thereby
analyzing the different let-7 miRNA family members (Table S1)
with regard to their sequence-dependent potential to activate mi-
croglia. We observed that other family members besides let-7b,
which lack this GUUGUGU motif, also activate microglia in a
TLR7-dependent fashion. Specifically, the core motifs of let-7a,
let-7c, let-7e, let-7f, and let-7g do not contain the last guanine
and/or uridine. In addition, let-7f and let-7g do not possess gua-
nine in the first position of the motif, and let-7d, which does not
activate TLR7, contains a cytosine instead of the third uridine (Fig-
ure 5A). As TLR7-dependent microglial activation was induced by
let-7e but not let-7d, we hypothesized that the UUGU motif is
responsible for microglial activation. To confirm this, we synthe-
sized let-7d and let-7e mutant oligoribonucleotides: let-7d-mut-
N (UUGC mutated to UUGU), let-7e-mut-N (UUGU mutated to
AUGU), and let-7e-mut-CS (no mutation in the UUGU motif but
upstream to this sequence) (Figure 5B). As expected, a point mu-
tation in the let-7d coremotif induced TLR7 activation and subse-
quent TNF-a release from microglia. In contrast, the point muta-
tion in the let-7e core motif reduced TNF-a release. The
mutation of six nucleotides at the 50 end of let-7e-mut-CS did
not affect TNF-a levels compared with stimulation with the un-
modified let-7e oligoribonucleotide, indicating that the presence
of theUUGUcoremotif is sufficient for TLR7-dependentmicroglia
activation (Figure 5C). In conclusion, these data imply that only the
core sequence of four nucleotides, namely, UUGU, is required for
let-7miRNA-induced activation of microglia through TLR7. These
findings are in accordance with those of previous studies that
identified the sequence UUGU as minimum motif required for
TLR7/TLR8-mediated cytokine responses mediated by human
peripheral blood mononuclear cells (Forsbach et al., 2008). This
selectivity is important because it supports a model in which
different let-7miRNA family members have unique roles in modu-
lating microglia function. Our finding that the UUGU sequence is
required as a minimum core motif for let-7-induced microglial
activation is relevant to our overall understanding of the specificity
of the interactions between an extracellular miRNA and its
cognate receptor, especially in the setting of brain diseaseCell Reports 29, 3460–3471, December 10, 2019 3465
Figure 6. let-7b and let-7e Are Differentially Expressed in GBM and
Act as Signaling Molecules on Glioma-Associated Microglia and
Macrophages
(A and B) Relative let-7b, let-7d, and let-7e expression levels were assessed in
(A) tumor tissue from GBM patients and control tissue (patients with epilepsy)
and (B) tumor tissue from the murine glioma models GL261 or RCAS-hPDGFb
and in healthy murine brain tissue.miR-16was used as housekeeping control.
n = 5 for human tissue samples, and n = 5–8 for mouse tissue samples of both
glioma models. Data are represented as mean ± SEM. Human data were
analyzed using the Mann-Whitney U test. Mouse data were analyzed using
one-way ANOVA followed by Dunnett’s post hoc test. *p < 0.05, **p < 0.01, and
***p < 0.001 versus control.
(C) Freshly isolated naive microglia (black), GL261-derived glioma-associated
microglia (dark gray), or glioma-associated macrophages (light gray) were
stimulated with 5 mg/mL let-7b, let-7d, or let-7e for 24 h. LPS (100 ng/mL), LOX
(1 mM), and mut. oligo (5 mg/mL) and LyoVec were used as positive and
negative controls, respectively. TNF-a was detected using ELISA. n = 3–6.
Data are represented as logarithm of mean ± SEM. The Kruskal-Wallis
test followed by Dunn’s post hoc test was used within each group. *p < 0.05,
**p < 0.01, and ***p < 0.001 versus respective control condition. The
Mann-Whitney U test was performed comparingGAMs versus naivemicroglia.
#p < 0.05, ##p < 0.01, and ###p < 0.001 versus naive microglia.
See also Figure S5.pathogenesis in which different let-7molecules may be released.
These findings provide potential new targets for therapeutic stra-
tegies, such as the development of inhibitor/agonist miRNAs as
modulators of microglial activation in specific CNS disorders.
let-7miRNAs Are Differentially Expressed in Glioma and
Induce TNF-a Release from Glioma-Associated
Microglia and Macrophages
On the basis of our previous studies on let-7b as a signaling
molecule for neurons (Lehmann et al., 2012a), we suggest that
CNS cells, including immune cells, release let-7 miRNAs into
the extracellular space, resulting in microglia activation. Whether3466 Cell Reports 29, 3460–3471, December 10, 2019cellular let-7 miRNAs passively leak into the extracellular space
of the CNS or are actively secreted in their native state or en-
closed in vesicles is unclear (Carlsbecker et al., 2010; Mittel-
brunn et al., 2011). It has been recently shown that lung tumor
cells release miR-21 and miR-29a inside exosomes. These
miRNAs are phagocytosed bymacrophages and activatemurine
TLR7 and human TLR8 (Fabbri et al., 2012). Whether this mech-
anism plays a role in let-7-mediatedmicroglial activation remains
to be elucidated. Our results extend the physiological role of let-7
miRNAs beyond their established role in regulation of gene
expression to ligand-mediated activation of receptors in micro-
glia. let-7 miRNAs function as signaling molecules in the brain,
where they modulate CNS pathology and contribute to injury, tu-
mor growth, and immune responses. It is well established that
microglia/brain macrophages are highly abundant in brain tumor
tissue, where they promote glioma growth (Hambardzumyan
et al., 2016). There are various cellular interactions between mi-
croglia/brain macrophages and glioma cells mediated by several
signaling molecules, including osteopontin or versican (Hu et al.,
2015; Szulzewsky et al., 2018). Furthermore, let-7 miRNAs are
differentially expressed in GBM and inhibit tumor growth by
gene silencing (Degrauwe et al., 2016; Lee et al., 2011; Mao
et al., 2013; Song et al., 2016; Wang et al., 2016). Building
upon our results, demonstrating that extracellular let-7 miRNAs
function as signaling molecules for microglia and macrophages,
we next sought to translate these findings to the setting of gli-
oma. We comparatively assessed the expression levels of the
let-7miRNA family members in brain tissue derived from human
glioma resection and in experimental mouse glioma models. Tu-
mor samples from GBM patients, as well as tissue from the syn-
geneic GL261 and the induced RCAS/TV-a system mouse gli-
oma models, were compared with control cortex tissue from
patients with epilepsy and samples from healthy murine brain,
respectively, using TaqMan PCR (Figures 6A and 6B). In human
GBM samples, let-7b, let-7d, and let-7e expression levels were
lower compared with control (Figure 6A). In glioma tissue derived
from the murine GL261 model, let-7b expression was lower (Fig-
ure 6B; for let-7b copy numbers, see Figure S5A), while the other
let-7 miRNAs showed no altered expression relative to control
(Figure 6B). In glioma tissue from the murine RCAS model, let-
7d and let-7e expression levels were lower compared with con-
trol (Figure 6B). let-7g andmiR-98miRNA expression levels were
lower in human GBM tissue, whereas in the RCAS model, tissue
let-7a, let-7c, let-7g, and miR-98 expression levels were lower
relative to control (Figure S5B). In glioma tissue from the
GL261 model, let-7c expression was lower, and let-7g expres-
sion was higher compared with control (Figure S5B). Expression
levels of miR-21 and miR-210, two established glioma-associ-
ated miRNAs (Malzkorn et al., 2010), were higher in human
GBM and murine glioma tissue compared with control (Fig-
ure S5B). As noted above, we observed a TLR7-dependent in-
duction of TNF-a from neonatal and adult microglia, as well as
from macrophages, exposed to let-7. To determine how let-7
miRNAs affect the function of glioma-associated microglia
and macrophages (GAMs), GL261-associated microglia and
invading macrophages, as well as freshly isolated naive micro-
glia, were incubated with let-7b, let-7d, or let-7e, and TNF-a
levels were measured in the respective supernatants using
ELISA. Microglia and macrophages both expressing GFP and
only macrophages expressing RFP were isolated from
Cx3CR1-GFP x Ccr2-RFP mice using FACS (Figure 6C).
Compared with controls, GAMs released TNF-a in response to
let-7b or let-7e exposure. The extent of these responses were
similar to those seen following LPS and LOX treatment. Naivemi-
croglia responded to let-7b and let-7ewith TNF-a release similar
to that observed in postnatal and adult microglia (see Figure 2).
Overall, the extent of TNF-a release from naive microglia in
response to the let-7 miRNAs tested was lower than those
induced in GAMs (Figure 6C). let-7d did not induce TNF-a
release relative to control. As observed for let-7 miRNAs, levels
of TNF-a induced by LPS and LOX in GAMs were also higher
compared with those induced in naive microglia (Figure 6C). In
summary, in human GBM and murine glioma, expression levels
of a specific subset of let-7 miRNAs including let-7b and let-7e
were lower relative to control. These let-7miRNAs not only main-
tained their ability to activate microglia from glioma tissue but
were even more potent inducers.
Extracellularly Delivered let-7b and let-7e Decrease
GL261Glioma Growth through TLR7 inMicroglia Ex Vivo
To assess the functional impact of let-7b, let-7e, and let-7d as
signaling molecules on glioma growth, we used organotypic
mouse brain slice cultures injected with mCherry-labeled
GL261 glioma cells. In this experimental paradigm, let-7b, let-
7d, or let-7e oligoribonucleotides were constantly present in
the culture medium. Four days after tumor injection, tumor vol-
ume using three-dimensional (3D) surface reconstruction was
determined (Figure 7A). let-7b and let-7e treatment resulted in
reduced tumor volume compared with untreated slices. In
contrast, let-7d treatment had no effect on tumor growth (Figures
7A and 7B). To investigate whether let-7miRNA-mediated tumor
reduction was dependent on TLR7, Tlr7/ brain slices injected
with mCherry-GL261 tumor cells were also treated with extracel-
lularly delivered let-7b, let-7d, or let-7e and analyzed as above.
Tumors from Tlr7/ brain slices did not show any significant
change in volume when treated with let-7b, let-7d, or let-7e rela-
tive to control (Figure 7B), indicating that TLR7 is required for the
let-7b- and let-7e-mediated reduction of the tumor volume
ex vivo. To assess whether microglia are required for let-7
miRNA-mediated tumor reduction, organotypic brain slices
from WT mice were treated with clodronate-loaded liposomes
for 24 h, followed 48 h later by the injection of glioma cells. As
described previously (Markovic et al., 2005), tumors in micro-
glia-depleted slices were smaller relative to microglia-containing
slices, and tumor growth was not affected following exposure to
let-7b, let-7d, or let-7e relative to controls (Figure 7B), demon-
strating that microglia account for tumor reduction induced by
extracellular let-7b and let-7e.
To further investigate the effect of let-7 as amicroglia signaling
activator on glioma growth, we performed immunohistochemical
analysis of the organotypic brain slices implanted with GL261
cells, as described above. Here, we focused on let-7b, the
most prominent member of the let-7 miRNA family, which
showed strong effects with respect to microglial activation and
glioma growth inhibition. Glioma treated with extracellularly
delivered let-7b revealed increased TUNEL-positive apoptosisand caspase-3 activation (Figure 7C). These effects were not
observed in brain slices incubated with let-7d (Figure 7C), which
did not activate microglia and did not affect GL261 tumor
growth. We detected reduced cell viability (Figure 7D) and
increased TUNEL-positive apoptosis and caspase-3 activation
(Figure 7E) in GL261 cells following exposure to microglia-condi-
tioned medium treated with extracellularly delivered let-7b.
Again, this effect was sequence dependent, as let-7d did not
induce such effects (Figures 7D and 7E).
Although TLR7 is expressed in neurons and microglia, little
or no TLR7 expression has been reported in astrocytes (Car-
pentier et al., 2005; Lehmann et al., 2012a; Olson and Miller,
2004). To validate these findings, we measured TLR7 expres-
sion in microglia and astrocytes isolated from postnatal day
(P) 14- and 12-week-old mice, as well as in GL261 and
RCAS glioma cells, using qRT-PCR (Figure S6). Microglia
from both P14- and 12-week-old mice expressed high levels
of TLR7, whereas neonatal astrocytes and adult astrocytes
expressed no or only low levels of TLR7, respectively. In
GL261- and RCAS-derived glioma cells, TLR7 expression
was not detectable (Figure S6).
In summary, our results imply a functional role for let-7
miRNAs as signaling molecules in glioma. Specific extracellu-
larly delivered let-7 miRNAs not only mediate the interaction
between microglia and glioma cells but also selectively sup-
press mouse glioma growth through microglial TLR7
signaling. Although we detected let-7b-mediated caspase-
3-positive apoptosis in both the GL261 glioma model and in
GL261 cells in vitro, the identification of the exact molecular
mechanism responsible for the glioma reduction induced by
extracellular let-7 miRNAs will require further investigation. It
is tempting to speculate that select let-7 miRNAs serving as
signaling molecules specifically reprogrammed microglial
cytokine release, migration, and antigen presentation in a
fashion that may have affected tumor growth. Moreover,
let-7 miRNA family members act as chemoattractants for mi-
croglia and could increase microglia infiltration in glioma. In
addition to the let-7 miRNAs’ impact on tumor growth as
TLR7 signaling activators, in their function as gene regulators
on a posttranscriptional level they may directly target onco-
gene expression. Indeed, let-7 miRNAs have anti-tumorigenic
effects in GBM cells by silencing stem cell programs, such as
reducing RAS (Lee et al., 2011) or E2F2 (Song et al., 2016)
expression. Thus, a greater understanding of the let-7
miRNAs’ role in both direct microglia signaling and posttran-
scriptional changes may reveal potential roles for them as
new therapeutic targets for GBM patients (Gilles and Slack,
2018).
Conclusion
let-7miRNAs in their unconventional form as signalingmolecules
differentially induce microglial activation mediated by TLR7 in a
sequence-dependent fashion, thereby modulating diverse func-
tions of these cells, including inflammatory responses, migration,
and antigen presentation. Translating these findings to a CNS
disease context, we found that select let-7 miRNAs serving as
signaling activators of microglia attenuate glioma growth. Future
studies will be required to define the mechanisms underlying theCell Reports 29, 3460–3471, December 10, 2019 3467
Figure 7. let-7b and let-7e Inhibit Glioma Growth through TLR7 and Microglia
(A) Three-dimensional surface reconstruction of glioma tumors in organotypic brain slices from WT mice incubated with let-7b, let-7d, or let-7e for 4 days post-
tumor injection. Scale bar, 500 mm.
(B) Quantification of tumor volumes in WT, Tlr7/, and microglia-depleted WT organotypic brain slices treated with 5 mg/mL let-7b, let-7d, or let-7e. Data are
represented as mean ± SEM. Brain slices from n = 4–8 biological replicates. *p < 0.05, **p < 0.01, and ***p < 0.001 versus control (one-way ANOVA followed by
Bonferroni post hoc test).
(C) OrganotypicWT brain slices implanted with mCherry GL261 cells and incubated with let-7b or let-7d for 4 days were stained with TUNEL assay (upper image)
and immunostained with activated caspase-3 antibody (lower image), as well as DAPI. Scale bar, 50 mm. Quantification of TUNEL-positive (upper graph) and
activated caspase-3-positive (lower graph) cells. Data are represented asmean ±SEM. Brain slices from n = 4 biological replicates. *p < 0.05 versus control (one-
way ANOVA followed by Bonferroni post hoc test).
(D) Viability of GL261 tumor cells treated with let-7b-, let-7d-stimulated microglial conditioned medium (MCM) or control MCM for 24, 48, and 96 h. Data are
represented as mean ± SEM; n = 4. *p < 0.05 and ***p < 0.001 versus control (one-way ANOVA followed by Bonferroni post hoc test).
(E) GL261 cells were treated with let-7b-, let-7d- MCM or control MCM for 48 h. Cells were stained with TUNEL assay (upper image) and immunostained with
activated caspase-3 antibody (lower image). Scale bar, 50 mm. Quantification of TUNEL-positive (upper graph) and activated caspase-3-positive (lower graph)
cells. Unstimulated GL261 cells and control MCM were used as controls. Data are represented as mean ± SEM; n = 6 or 7. *p < 0.05 versus control (one-way
ANOVA followed by Bonferroni post hoc test). n.s., not significant.
See also Figure S6.
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let-7 miRNAs’ regulatory roles as signaling molecules in micro-
glia in health and disease.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
C57BL/6J (wild-type, WT), as well as Tlr7/, Tlr2/ and Tlr4/mice were used for microglial primary cultures. Neonatal microglia
were isolated from male and female mice, while adult microglia were derived from male mice. For the acute isolation of adult
microglia, Cx3cr1GFP/+ x Ccr2RFP/+ male mice were used. For the generation of primary gliomas using the RCAS/Tv-a system,
Nestin-tv-a;Ink4a-Arf/;Ptenfl/fl male mice were employed. For organotypic brain slice cultures, transgenic male mice expressing
EGFP under the Csf1r promoter (MacGreen) were used. All animals were maintained and handled in accordance with the German
Animal Protection Law and approved by the Regional Office for Health and Social Services in Berlin (Landesamt f€ur Gesundheit
und Soziales – LaGeSo, Berlin, Germany).
Human Biopsies
Freshly resected samples from male patients with glioblastoma were provided by the Department of Neurosurgery, Helios Clinic
Buch (Berlin, Germany) and the Department of Neurosurgery, University Medical Center Schleswig-Holstein (Kiel, Germany). Brain
samples from male patients with epilepsy were provided by the Department of Neurosurgery, Charite´-Universita¨tsmedizin Berlin
(Berlin, Germany). The samples used here were small fragments from tissue blocks. The study has complied with all relevant ethicale3 Cell Reports 29, 3460–3471.e1–e7, December 10, 2019
regulations and was approved by the institutional review boards. Written informed consent was obtained from all patients partici-
pating in the study.
Cell Lines
For fluorescence labeling, GL261 cells (Charles River Laboratory, Wilmington, MA, USA) were lentivirally transduced with a plasmid.
Briefly, themCherry gene was cloned into a lentiviral vector on a pRRL backbone (https://www.addgene.org/12252/), downstream of
the MP71 promoter. After the production of viral particles, WT GL261 cells were transduced for 24 h at a MOI of 1 by using RPMI
medium supplementedwith 10% fetal calf serum, 2%Glutamin, 1%antibiotics Penicillin and Streptomycin, and 0.4mg/ml Polybrene
(Merck, Darmstadt, Germany). Transductionwas stopped by adding new freshmedium.Mcherry-labeledGL261 cells (information on
the sex of origin is unavailable) were selected via FACS cell sorting and frozen until further use.
Primary Cell Cultures
Neonatal primary microglial cultures from WT and TLR2-, TLR4-, and TLR7-deficient mice were prepared as previously described
(Ifuku et al., 2016; Prinz et al., 1999). Briefly, brains, including cortex and midbrain, from postnatal day 0-2 (P0-P2) male and female
newborns were freed of blood vessels and meninges, mechanically dissociated into 1 mm3 pieces and digested with 1% trypsin and
0.05% deoxyribonuclease. Digested tissue was further mechanically dissociated with a fire-polished pipette and washed twice in
HBSS. Mixed glial cultures were plated and cultured for 9-12 d in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal calf serum and 1% antibiotics Penicillin and Streptomycin. After 7 d, 33% L292-conditioned medium was added
to the cultures, and the microglial cells were isolated by gentle shaking at 37C for 1 h on a shaker (100 rpm) and plated.
Microglia from adult mice were prepared as described previously (Pannell et al., 2016). In short, brains obtained from adult male
mice (P49-56) were freed of blood vessels and meninges, mechanically dissociated, and digested with trypsin and DNase as
described for neonatal cultures. After further dissociation cells were plated on a confluent monolayer of P0-P2 astrocytes in
75 cm2 flasks. The feeder astrocytic layer was depleted of neonatal microglial cells by using chlodronate (200 mg/ml) before plating
the microglial cells. Mixed adult and neonatal glial cultures were maintained in fresh complete DMEM, and the medium changed
every third day, followed by addition of 33% L292-conditioned medium at day 7. One week later, cells were shaken off and used
for experiments within 24-48 h.
Bone marrow-derived macrophages were isolated fromWT male adult mice (P49-59) as previously described (Manzanero, 2012).
Mice were sacrificed by cervical dislocation, and their back legs were removed by cutting near the pelvic area. The skin was removed
together with muscles, and ligaments, and the bone was cut below the ankle joint. The femur and tibia were isolated by slightly
bending the knee joint. Complete RPMI 1640 tissue culture medium, supplemented with 10% heat-inactivated fetal bovine serum
and 1% antibiotics, was flushed through the bone, and the contents collected into a sterile 15 mL polypropylene tube. After centri-
fugation for 5min at 1200 rpm, red blood cells were lysed by adding Erylyse Buffer for 3min and subsequently centrifuged for 5min at
1200 rpm. Cells were then passed through a 70 mm cell strainer and plated in 10 cm dishes with fresh complete RPMI medium
supplemented with 2 ng/ml of M-CSF to allow differentiation into macrophages. After 7 d, cells were trypsinized and used for exper-
iments within 1 d of plating.
METHOD DETAILS
Isolation of Fresh Naive Adult Microglia and GAMs for Functional Assays
Microglia were isolated from healthy or GL261 tumor-bearing Cx3cr1GFP/+ x Ccr2RFP/+malemice (P84). Micewere fully anaesthetized
with Narcoren (Merial GmbH, Hallbergmoos, Germany) and transcardially perfused with ice-cold 1x Phosphate Buffered Saline
(PBS). Brains were extracted, excluding the brain stem and cerebellum, and digested into a single cell suspension by using Adult
Brain Dissociation Kit mouse and rat (Miltenyi Biotech GmbH, Bergisch Gladbach, Germany) according to the manufacturer’s
manual. Briefly, the kit consists of one enzymatic digestion step by using gentleMACSTM Dissociator with heaters followed by a
debris and myelin removal step. Dissociated cells were directly isolated via Fluorescent-activated cell sorting (FACS) by using
FACS Aria flow cytometer (BD Bioscences, San Jose, USA). The gating strategy used the GFP/RFP ratio from the reporter mice. Mi-
croglia, defined as the GFPhighRFP- population, and invading macrophages, defined as the GFPhighRFP+ population, were sorted in
fresh complete DMEM supplemented with antimycotics and antibiotics. Following centrifugation at 500 g for 5 min, 5x104 microglial
cells were plated in a 96-well-plate, and used for experiments 24 hr later.
Microglia and astrocytes from P14 and 12-week-old WT male mice were isolated via FACS sorting by using the following dye-
coupled antibodies: CD11b, CD45 (eBioscience, San Diego, USA), and ACSA2 (Miltenyi Biotech GmbH, Bergisch Gladbach,
Germany).
let-7 miRNA Stimulation and TNF-a Enzyme-Linked Immunosorbent Assay
To test let-7miRNA-mediated cell activation in vitro, we stimulated cells, collected the supernatant and tested for TNF-a release via
an ELISA assay. Neonatal and adult primarymicroglia as well as bonemarrow-derivedmacrophages were plated into a 96-well-plate
at a density of 3x104 cells per well in 150 ml medium, while acutely isolated adult microglia were plated in a 96-well-plate at a density of
5x104 cells per well. To assess the time course, cells were stimulatedwith 660 nMof let-7 oligoribonucleotide for 9 h, 24 h and 30 h. ToCell Reports 29, 3460–3471.e1–e7, December 10, 2019 e4
characterize the dose response, cells were stimulated for 24 h with increasing concentrations of the respective miRNA (1, 5 and
10 mg/ml corresponding to 132, 660, and 1320 nM, respectively). At the appropriate time point, supernatants were collected and
tested for TNF-a concentration, expressed in ng/ml, using an enzyme immunosorbent assay (ELISA) and themouse TNF alpha ELISA
Ready-SET-Go!TM kit (Affymetrix eBioscence, San Diego, CA, USA) according to themanufacturer’s manual. For treatment of GL261
cells with microglial conditioned medium (MCM), microglia were plated in a 6-well-plate at a density of 1x106 cells per well and stim-
ulated with 5 mg/ml let-7b or let-7d oligoribonucleotide for 24 h.
Multiplex Immune Assay
Detection of cytokines in supernatants collected from microglial cell cultures stimulated over time with let-7miRNA family members
was performed using the ProcartPlexmouseMultiplex ImmunoassayMix&Match (Affymetrix eBioscience, Vienna, Austria) according
to the manufacturer’s manual. Briefly, the magnetic beads-based assay enables the simultaneous detection and quantification of
multiple proteins in a single sample. Prior to incubation, samples were vortexed followed by centrifugation to remove particles.
Detection of the proteins was performed by using Luminex 200. Analysis was performed by using Bioplex System Software 4.0
(Bio-Rad, Hercules, CA, USA). The cytokine analysis included TNF-a, IL-6, IL-10, IL-1b, GRO-a, MIP-2, RANTES, GM-CSF, IP-10,
MCP-1, MCP-3, MIP-1a, and MIP-1b. Expression levels are shown as Mean Fluorescent Intensity (MFI).
Agarose Spot Assay
Agarose spot assay was performed as previously described (Wiggins and Rappoport, 2010). In summary, 0.1 g of low-melting point
agarose (Promega, Madison, WI, USA) was diluted in 20 mL of PBS originating 0.5% agarose solution. The solution was then heated
until boiling and subsequently cooled down to 40C. Afterward, 90 ml of agarose solution was mixed with 10 ml of PBS with or without
let-7miRNAs (at a concentration of 660 nM) in a 0.5 mL Eppendorf tube. 10 ml of mixed solution were rapidly plated into 35 mm glass
bottomed dishes (Maktek Corporation, Ahland, MA, USA) and were cooled down for 10 min at 4C. Four spots were pipetted in one
dish, two containing PBS only and twowith selected let-7 oligonucleotides. 5x105microglia cells fromWTor Tlr7/micewere plated
in the dish in 2 mL DMEM supplemented with 10% fetal calf serum and incubated at 37C for 3 h. Subsequently, the cells inside the
spot were counted under the microscope. To assess microglial motility, we also applied the respective oligoribonucleotide to the
medium. For chemotaxis assays, let-7 oligoribonucleotides or mutant oligoribonucleotide, with or without RNase A (10 mg) pre-treat-
ment, were only present inside the spot.
Flow Cytometry Analysis
Neonatal primary microglial cultures from WT and Tlr7/ mice were prepared as previously described (see above) and seeded at a
confluency of 5x105 cells in a 35 mm Petri dish. Microglia were stimulated with let-7b, let-7d and let-7e (660 nM) for 24 h followed by
cell collection by scratching in ice-cold PBS and centrifugation at 500 g for 5 min at 4C. The cell pellet was resuspended in ice-cold
FACS buffer (PBS supplemented with 1% fetal calf serum) and divided in two groups (each group contained 2x105 cells), for immu-
nolabeling with the following dye-coupledmonoclonal anti-mouse antibodies: CD45, CD11b, MHC I, MHC II and CD54 (eBioscience,
San Diego, USA) for 20min at 4C. Next, cells were immediately acquired on a LSRII flow cytometer (BD Bioscience, San Jose, USA),
and the data analyzed using FlowJo v10 software (Tree Star). Expression values are shown asMFI normalized to unstimulated control
condition.
Tumor Injection In Vivo
Tumors were inoculated in vivo as previously described (Szulzewsky et al., 2015). Injections were performed using a
stereotactic frame (Stoelting, Wood Dale, IL, USA). Mice used for these experiments were 8-14-week old (C57BL/6 mice and
Cx3cr1GFP/+x Ccr2RFP/+ for GL261 cell injection, C57BL7/6 mice for RCAS-PDGFb tumor cell re-implantation) or 4.5-10-week-old
(Ntv-a/Ink4a-Arf/ mice for DF-1 RCAS-PDGFb injection). Mice were anaesthetized with intraperitoneal injections of ketamine
(0.1 mg/g, Pharmazeutischen Handelsgesellschaft, Garbsen, Germany) and xylazine (0.02 mg/g, Bayer, Leverkusen, Germany).
Animals were also treated with 0.25% Marcaine (volume about 0.1 ml/25 g) administered right before the surgery.
Onemicroliter cell suspensions (2x104 GL261 cells, 43 104 transfected DF-1 cells, or 5x104 RCAS-PDGFb tumor cells) were deliv-
ered using a 30-gauge needle attached to a Hamilton syringe (Hamilton, Reno, NV, USA). Coordinates for GL261 injections into
C57BL/6 mice were bregma 1 mm anterior, Lat (lateral) 2 mm (right of midline), and a depth 3 mm from the dural surface.
Coordinates for injections of DF-1 cells and RCAS-PDGFb tumor cells into Ntv-a/Ink4a-Arf/mice andC57BL/6mice, respectively,
were bregma 1.5 mm anterior, Lat 0.5 mm, and a depth 2.0 mm. Mice were monitored daily for the first two weeks and twice a day
starting from day 15 post-injection for symptoms of tumor development (lethargy, hydrocephalus, head tilting). At day 18-19 and day
30 for GL261 and RCAS, respectively, animals were sacrificed and perfused with 1x PBS followed by decapitation and brain
resection.
Total RNA Extraction and Quantitative RT-PCR
For let-7 expression analysis in human and murine brain samples, we extracted total RNA with the mirVanaTM PARISTM kit (Thermo
Fisher Scientific, Waltham, MA, USA), according to the manufacturer’s protocol. Briefly, human and murine brain samples were
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rapidly into Cell Disruption Buffer. The mixture was then homogenized by using Ultra-Turrax (Merck, Darmstadt, Germany) at
21.500 rpm for 30 s. Once the lysate was homogenized, equal volume of 2x denaturating solution and incubated on ice for 5 min.
Next, the sample lysate plus 2x denaturating solution was mixed with an equal volume of Acid-Phenol:Chloroform and vortexed
for 60 s. After a centrifugation step of 5 min at maximum speed at room temperature, the upper aqueous phase was collected
and transferred to a new tube. 1.25 volumes 100% ethanol were added to the aqueous phase, and the mixture was placed into
the filtered column and centrifuged for 30 s at 10.000 g at room temperature. The column was then washed with miRNA Wash
Solution 1 and 2/3 and ultimately eluted with RNase free water. Total RNA amount was quantified with the Thermo ScientificTM
NanodropTM One spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). Reverse transcription and quantitative PCR
was performed using the TaqMan MicroRNA Assay, according to the manufacturer’s manual. Taqman PCR reactions were
performed in the Step one Plus Real Time PCR system (Applied Biosystems, Foster City, CA, USA). Expression data were normalized
to miR-16 for each sample.
For detection of TLR7 expression in freshly isolated microglia, astrocytes, and the tumor cell lines GL261 and RCAS, cDNA was
obtained using the SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions. Quantitative real-time PCR was performed in a 7500 Fast Real-Time
thermocycler (Applied Biosystems, Foster City, CA, USA) using SYBR select Master Mix (Applied Biosystems, Foster City, CA,
USA). TATA-binding protein (TBP) was used as housekeeping gene. The following primers (synthesized by Biotez GmbH, Berlin,
Germany) were used: mTLR7 forward 50-ATGTGGACACGGAAGAGACAA-30, mTLR7 reverse 50-GGTAAGGGTAAGATT
GGTGGTG-30, TBP forward 50-AAGGGAGAATCATGGACCAG-30, TBP reverse 50- CCGTAAGGCATCATTGGACT-30.
Analysis of Cell Viability and Apoptosis in GL261 Cells
GL261 cells were treated with microglial conditionedmedium (MCM) stimulated with select let-7 oligoribonucleotides, as indicated in
the Figure legend, and cell viability and apoptosis rate were assessed. For viability assay, GL261 cells were plated in a 96-well-plate
at a density of 1x104 cells/well and treated with 100 ml of let-7-stimulated MCM for 24, 48 and 96 h. At each time point, 10 ml of Cell
Counting Kit-8 (CCK8, Tebu-Bio, Offenbach, Germany) reagent was added. After 2 h, absorbance was measured at 450 nm on a
microplate reader (TECAN). Values were normalized to the unstimulated condition. For cell death analysis, GL261 cells were plated
in a 24-well-plate at a density of 5x104 cells/well and treated with 300 ml of let-7-stimulated MCM for 48 h. Subsequently, cells were
fixed in 4%PFA and analyzed by TUNEL assay and immunostaining employing an antibody against activated caspase-3 (see below).
Organotypic Brain Slice Cultures
Organotypic brain slice preparation was performed as previously described (Markovic et al., 2005). Briefly, brains derived from
P14-16 MacGreen animals were removed and placed in ice-cold PBS. Cerebellum and olfactory bulb were removed, and the fore-
brain was placed on a glass block and cut in the coronal plane into 250 mm sections with a vibratome (Microm HM650V, Thermo
Scientific, Waltham, MA, USA). Brain slices were transferred onto 0.4 mm polycarbonate membranes in the upper chamber of a
transwell tissue insert (Falcon model 3090, Becton Dickinson, Franklin Lakes, NJ, USA), which was inserted into a 6-well-plate
(Falcon model 3502, Becton Dickinson, Franklin Lakes, NJ, USA). To ensure the same experimental conditions three slices, repre-
senting three different brain areas, were mounted on each insert. Thereafter, brain slices were incubated in 1 mL of culture medium
per well containing DMEM supplemented with 10% heat-inactivated fetal bovine serum (Atlanta Biological, Norcross, GA), 0.2 mM
glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin (medium-1). After overnight equilibration of the brain slices in medium-1,
slices were incubated with cultivation medium-2. Medium-2 contained 25% heat-inactivated horse serum, 50 mM sodium bicarbon-
ate, 2% glutamine, 25% Hank’s balanced salt solution, 1 mg/ml insulin, 5 mM Tris (all from Life Technologies, Carlsbad, CA, USA),
2.46 mg/ml glucose (Braun Melsungen, Germany), 0.8 mg/ml vitamin C, 100 U/ml penicillin and 100 mg/ml streptomycin (all from
Sigma-Aldrich, St. Louis, MO, USA) in DMEM (GIBCO, Thermo Fisher Scientific, Waltham, MA, USA). Slices were maintained in cul-
ture for 5 d with medium change every two days.
Tumor Cell Injection into Brain Slices and let-7 miRNA Treatment
One day after sectioning, 5000 cultured mCherry GL261 glioma cells in a volume of 0.1 ml were injected into the slices using a micro-
syringe mounted to a micromanipulator. An injection canal was formed that reached 150 mm deep into the 250-mm-thick slice. The
needle was then retracted by 50 mm, leaving an injection cavity of approximately 50 mmwhere the tumor cell suspension was slowly
inoculated over 30 s. Afterward, the syringe was pulled out in 10 mm incremental steps over 60 s. To ensure identical experimental
conditions, gliomas were always inoculated in the striatal area of both hemispheres. In parallel to tumor inoculation, the let-7miRNAs
complexed with Lyovec were added to the medium at a concentration of 0,5 mg/ml and replenished when fresh new medium was
changed so that the let-7 oligoribonucleotides were constantly present.
Depletion of Microglia
For microglial depletion, clodronate-loaded liposomes (Liposoma, Amsterdam, Netherlands) were used. Brain slices were incubated
with the liposomes for 24 h at 37C. Afterward, slices were incubated with medium-2 (see above) for equilibration, with glioma cell
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Immunofluorescence, Confocal Microscopy, and Tumor 3D Reconstruction
GL261 cells seeded on coverslips and treated with let-7-stimulated MCMwere fixed for 10 min in 4% PFA, washed 3x with PBS and
incubated for 1 h at room temperature in permeabilization/blocking solution (5% normal donkey serum and 0.2% Triton X-100
D-PBS). Subsequently, anti-rabbit activated caspase-3 antibody was added to the permeabilization/blocking solution (1:300), and
cells were incubated at 4C overnight. This step was followed by adding DAPI solution (1:5000; Sigma-Aldrich, St. Louis, MO,
USA) and donkey anti-rabbit Alexa Fluor 647 (1:500) incubation at room temperature. Afterward, coverslips were mounted and
analyzed at the confocal microscope. For TUNEL analysis, In Situ Cell Death Detection Kit, Fluorescein (Roche, Basel, Switzerland)
was used, according to the manufacturer’s manual. Briefly, cells were permeabilized and blocked in a D-PBS solution containing
0.1% sodium citrate and 0.1% Triton X-100 for 3 min on ice. Afterward, cells were incubated with the TUNEL reaction mixture for
1 h at 37C, followed by 3x washing with D-PBS, and incubation with DAPI solution, before mounting on a glass slide.
Organotypic brain slices were fixed at day 4 post-injection with 4% PFA for 1 h followed by PBS washing and incubation overnight
at 4C with D-PBS supplemented with 5% donkey serum and 0.3% Triton X-100. Slices were incubated with anti-rabbit activated
caspase-3 primary antibody (1:100) for 24 h followed by 3x washing with D-PBS. Incubation with donkey anti-rabbit Alexa Fluor
647 secondary antibody (1:250) was performed for 2 h at room temperature. In addition, staining with DAPI was performed for 2
h. For TUNEL staining, ApopTag Plus Fluorescein In Situ Apoptosis Detection Kit (Merck, Darmstadt, Germany) was used following
the manufacturer’s instructions. Briefly, after 1 h fixation in 4% PFA, slices were incubated for 10 min at room temperature with
permeabilization buffer containing ethanol: acetic acid, 2:1 (v:v). Slices were incubated for 1 min with equilibration buffer and
subsequently incubated with the TUNEL reaction mixture (TdT enzyme and reaction buffer) for 2 h at 37C in a humidified chamber.
The reaction was stopped by incubating the slices with the stop/wash buffer for 15 min at room temperature. Finally, anti-digoxige-
nin-conjugated solution was applied on the slices for 30 min at room temperature. Slices were mounted for tumor volume quantifi-
cation and apoptosis analysis. Tumor volumes were determined by using the confocal laser microscopy scanning (Leica TCS SPE,
Leica Microsystems, Wetzlar, Germany). We acquired images with a 20x oil immersion objective by using a z stack with a 2 mm step
size interval and tile scan mode. Data analysis to assess tumor volume was performed by using Imaris 9 (Bitplane, Z€urich,
Switzerland). Tumor volumes of high-resolution SPE confocal microscopy stacks were 3D rendered by application of 1 mm object
detail, 15 threshold background and 1000 tridimensional pixels (voxels). The surface objects obtained were unified in one single ob-
ject, and volume mean values were extracted.
For apoptosis quantification in vitro and ex vivo, we acquired 4 images per coverslip/tumor at 20x and quantified by ImageJ soft-
ware with the additional threshold adjustment tool and cell counter plug in.
QUANTIFICATION AND STATISTICAL ANALYSIS
All experiments were performed at least three times, and all data were represented as mean ± SEM. We assessed statistical
significance by using Prism 7 Windows (GraphPad Software, San Diego, CA, USA). For ELISA and multiplex analysis we used
Kruskal-Wallis test followed by Dunn’s multiple comparison post hoc test. For migration studies, FACS analysis, viability/cell death
analysis, and comparison between organotypic brain slices, one way ANOVA followed by Bonferroni post hoc test, was performed.
For paired comparison in human and mouse quantitative PCR analysis, Mann Whitney U test or one way ANOVA followed by
Dunnett’s multiple comparison post hoc test was performed. Significance was set at p < 0.05.
DATA AND CODE AVAILABILITY
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